
Nova Eye Medical (ASX:EYE) is an Australian medical device company focused on the development and commercialisation of novel glaucoma treatment options. The company has a portfolio of proprietary technologies, including its iTrack and Molteno3 glaucoma devices, as well as its 2RT laser therapy for intermediate age-related macular degeneration. Nova Eye's operations are focused on the commercialisation of its existing products and the development of new technologies. The company has a global sales and marketing team in place to support the launch of its iTrack Advance canaloplasty device, which is expected to occur in early 2024.